# NCT03811002 (NCT03811002)

> Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03811002
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Limited Stage Lung Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8
- Interventions: 3-Dimensional Conformal Radiation Therapy; Atezolizumab; Biospecimen Collection; Carboplatin; Cisplatin; Etoposide; Intensity-Modulated Radiation Therapy; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 544
- Primary outcome: Overall Survival

## Commentary we found

- X threads: 24
- Podcasts: 20
- YouTube: 12

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03811002

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03811002", "email": "<work email>"}; the inbox owner confirms by the emailed link.